Adeno-Associated Virus (AAV) Gene Therapy

A Adeno-Associated Virus (AAV) Gene Therapy is a viral vector gene therapy that uses modified adeno-associated virus (to deliver therapeutic genes to target cells for genetic disease treatment).

• AKA: AAV Gene Therapy, AAV-Based Gene Therapy, AAV Vector Therapy.
• Context:
  • It can typically deliver Therapeutic Gene to target tissues through non-pathogenic viral vectors.
  • It can typically achieve Long-Term Gene Expression through episomal persistence or chromosomal integration.
  • It can typically offer Tissue-Specific Targeting through capsid engineering and promoter selection.
  • It can typically provide Transgene Expression with minimal immunogenicity compared to other viral vector systems.
  • It can typically maintain Therapeutic Effect through sustained protein production in non-dividing cells.
  • ...
  • It can often enable Single-Dose Treatment through durable gene transfer capabilities.
  • It can often accommodate Genetic Payload up to 4.7 kilobases in size.
  • It can often mediate Precise Gene Editing through CRISPR/Cas9 delivery to specific genomic locus.
  • It can often induce Immune Tolerance through liver-directed gene transfer and immunomodulatory approaches.
  • It can often resolve Genetic Deficiency through functional gene replacement or gene augmentation.
  • ...
  • It can range from being a Single-Serotype AAV Gene Therapy to being an Engineered AAV Gene Therapy, depending on its vector engineering approach.
  • It can range from being a Systemic AAV Gene Therapy to being a Localized AAV Gene Therapy, depending on its administration route.
  • It can range from being a Gene Replacement AAV Gene Therapy to being a Gene Editing AAV Gene Therapy, depending on its therapeutic mechanism.
  • It can range from being a First-Generation AAV Gene Therapy to being a Next-Generation AAV Gene Therapy, depending on its vector optimization level.
  • ...
  • It can have Serotype Tropism for specific tissue types through capsid protein variations.
  • It can provide Dose-Dependent Expression of therapeutic proteins via transcriptional regulation.
  • It can enable Programmable Gene Delivery through regulatory element incorporation and inducible systems.
  • It can overcome Pre-Existing Immunity through capsid engineering and immunomodulatory strategys.
  • It can support Dual Vector Approaches for large gene delivery exceeding packaging capacity.
  • ...
• Examples:
  • Adeno-Associated Virus (AAV) Gene Therapy Approved Products, such as:
    • Ocular Adeno-Associated Virus (AAV) Gene Therapys, such as:
      • Voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy treatment.
      • AAV5-hRKp.RPGR (Lumevoq) for X-linked retinitis pigmentosa treatment.
    • Neuromuscular Adeno-Associated Virus (AAV) Gene Therapys, such as:
      • Onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy treatment.
      • Roctavian (valoctocogene roxaparvovec) for hemophilia A treatment.
  • Adeno-Associated Virus (AAV) Gene Therapy Clinical Trials, such as:
    • CNS-Targeted Adeno-Associated Virus (AAV) Gene Therapys, such as:
      • AAV9-GAA Gene Therapy for Pompe disease treatment.
      • AAVrh10-SGSH Gene Therapy for mucopolysaccharidosis IIIA treatment.
    • Metabolic Adeno-Associated Virus (AAV) Gene Therapys, such as:
      • AAV8-OTC Gene Therapy for ornithine transcarbamylase deficiency treatment.
      • AAV5-hFVIII Gene Therapy for hemophilia B treatment.
  • Adeno-Associated Virus (AAV) Gene Therapy Preclinical Developments, such as:
    • Novel Adeno-Associated Virus (AAV) Gene Therapy Vectors, such as:
      • Ancestral AAV Gene Therapy for enhanced tissue penetration.
      • AAV-PHP.eB Gene Therapy for enhanced blood-brain barrier crossing.
    • Adeno-Associated Virus (AAV) Gene Therapy Delivery Systems, such as:
      • Exosome-AAV Hybrid Gene Therapy for improved targeting efficiency.
      • Nanoparticle-Encapsulated AAV Gene Therapy for enhanced delivery stability.
  • ...
• Counter-Examples:
  • Adenovirus Gene Therapy, which lacks long-term expression capability and has higher immunogenicity than adeno-associated virus (AAV) gene therapy.
  • Lentivirus Gene Therapy, which integrates into host genome unlike most adeno-associated virus (AAV) gene therapy that remains episomal.
  • Plasmid-Based Gene Therapy, which lacks viral packaging and has significantly lower transduction efficiency than adeno-associated virus (AAV) gene therapy.
  • mRNA Therapy, which delivers temporary genetic instructions rather than the durable gene transfer provided by adeno-associated virus (AAV) gene therapy.
• See: Viral Vector, Gene Transfer Technology, Genetic Disease Treatment, Therapeutic Protein Expression, In Vivo Gene Therapy.

---